ARTICLE | Product Development

Behind SAB’s rapid response to COVID-19

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 24, 2020 11:48 PM UTC

SAB had already been working with the U.S. Department of Defense to prepare its human polyclonal antibody platform for rapid responses to new infectious diseases when COVID-19 emerged. The company has since applied its DiversitAb platform to generate SAB-185, a cow-derived human polyclonal antibody therapy that is more consistent and easier to scale up than convalescent plasma from recovered COVID-19 patients.

SAB Biotherapeutics Inc. co-founder and CEO Eddie Sullivan told BioCentury it expects initial lots of SAB-185, which targets the SARS-CoV-2 spike protein, to be ready for clinical testing in early summer. ...

BCIQ Company Profiles

SAB Biotherapeutics Inc.